ReviewDrugs & aging2019
Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer.
Review in Drugs & aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.
- Safety and Effectiveness of Immune Checkpoint Inhibitors in Older Patients with Cancer: A Systematic Review of 48 Real-World Studies.Drugs & aging · 2021Pooled it
- Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.Journal of managed care & specialty pharmacy · 2021Trial
- Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Renal Cell Carcinoma in the Geriatric Population: Toward a Frailty-Adapted Therapeutic Paradigm.Journal of clinical medicine · 2026Review
- The Use and Utility of Adjuvant Checkpoint Inhibitors in Elderly Patients with Melanoma: A Single Institution Experience.Cancers · 2026Article
- Impact of geriatric impairments on outcomes of single-agent immunotherapy in solid tumors.International journal of cancer · 2026Article
- Understanding Cancer Care for Nursing Home Residents Living With Dementia: An Ethnographic Study.Psycho-oncology · 2025Article
- Off-Label Use of First-Line Immunotherapy for Metastatic Renal Cell Carcinoma.Clinical genitourinary cancer · 2025Article
- Prevalence of symptomatic toxicities for novel therapies in adult oncology trials: a scoping review.JNCI cancer spectrum · 2025Article
- Neurological complications in oncology and their monitoring and management in clinical practice: a narrative review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Review
- Toxicity in Older Patients with Cancer Receiving Immunotherapy: An Observational Study.Drugs & aging · 2024Observational
- Immunotherapy: should we worry about immunosenescence?Ageing and cancer research & treatment · 2024Article
- Immunotherapy in Older Patients with Cancer: A Narrative Review.International journal of general medicine · 2024Review
- Article
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in Older Patients: Are New Agents Bringing New Hope?Drugs & aging · 2023Review
- Intratumoral immunotherapy of murine pheochromocytoma shows no age-dependent differences in its efficacy.Frontiers in endocrinology · 2023Article
- Clinical and Therapeutic Considerations for Older Adults with Head and Neck Cancer.Clinical interventions in aging · 2023Review
- Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial.Liver cancer · 2022Article
- Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer.Cancers · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of older patients with cancer is increasing as a result of the ageing of Western societies. Immune checkpoint inhibitors have improved cancer treatment and are associated with lower rates of treatment-related toxicity compared with chemotherapy in the general population. Nonetheless, immune checkpoint inhibitors have potentially serious immune-related adverse events, which might have a greater impact on older and more vulnerable patients and potentially influence treatment efficacy and quality of life. Previous clinical trials have shown no major increase in immune-related adverse events; however, older patients are underrepresented and relatively healthy in these trials. Observational studies suggest that older and more vulnerable patients may be at a higher risk of immune-related adverse events and early treatment discontinuation. Geriatric assessment could help identify older patients who will benefit from immune checkpoint inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.